Literature DB >> 21948351

Considerations on what constitutes a 'qualified statistician' in regulatory guidelines.

Christoph Gerlinger1, Lutz Edler, Tim Friede, Meinhard Kieser, Christos T Nakas, Martin Schumacher, Jørgen Seldrup, Norbert Victor.   

Abstract

International regulatory guidelines require that a 'qualified statistician' takes responsibility for the statistical aspects of a clinical trial used for drug licensing. No consensus on what constitutes a 'qualified statistician' appears to have been developed so far. The International Society for Clinical Biostatistics is issuing this reflection paper in order to stimulate a discussion on the concept.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 21948351     DOI: 10.1002/sim.4345

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  The risks of methodology aversion in drug regulation.

Authors:  Peter Bauer; Franz König
Journal:  Nat Rev Drug Discov       Date:  2014-05       Impact factor: 84.694

2.  Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.

Authors:  Sanne Samuels; Balazs Balint; Heiko von der Leyen; Philippe Hupé; Leanne de Koning; Choumouss Kamoun; Windy Luscap-Rondof; Ulrike Wittkop; Ksenia Bagrintseva; Marina Popovic; Atttila Kereszt; Els Berns; Gemma G Kenter; Ekaterina S Jordanova; Maud Kamal; Susy Scholl
Journal:  Br J Cancer       Date:  2016-11-22       Impact factor: 7.640

3.  A proposal for a new PhD level curriculum on quantitative methods for drug development.

Authors:  T Jaki; A Gordon; P Forster; L Bijnens; B Bornkamp; W Brannath; R Fontana; M Gasparini; L V Hampson; T Jacobs; B Jones; X Paoletti; M Posch; A Titman; R Vonk; F Koenig
Journal:  Pharm Stat       Date:  2018-07-09       Impact factor: 1.894

4.  Comprehensive survey among statistical members of medical ethics committees in Germany on their personal impression of completeness and correctness of biostatistical aspects of submitted study protocols.

Authors:  Geraldine Rauch; Lorena Hafermann; Ulrich Mansmann; Iris Pigeot
Journal:  BMJ Open       Date:  2020-02-04       Impact factor: 2.692

Review 5.  Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.

Authors:  Juanita Lopez; Sam Harris; Desam Roda; Timothy A Yap
Journal:  Transl Oncogenomics       Date:  2015-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.